Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine
| Autor: | Max V. Rasmussen, William Hurtle, Mariceny Zurita, Damodar Ettyreddy, Christopher Schutta, Bruce G. Harper, David A. Brake, Barbara J. Kamicker, Melia Pisano, Douglas E. Brough, John G. Neilan, Bryan T. Butman, Carla Bravo de Rueda, José Barrera |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Serotype medicine.medical_treatment Genetic Vectors Cattle Diseases Biology Antibodies Viral Serogroup 03 medical and health sciences 0302 clinical medicine Adjuvants Immunologic medicine Animals 030212 general & internal medicine Vaccines Synthetic Dose-Response Relationship Drug General Veterinary General Immunology and Microbiology Foot-and-mouth disease Vaccination Public Health Environmental and Occupational Health Viral Vaccines Vaccine efficacy medicine.disease biology.organism_classification Antibodies Neutralizing Virology Diva 030104 developmental biology Infectious Diseases Gene cassette Foot-and-Mouth Disease Virus Foot-and-Mouth Disease Vaccines Subunit biology.protein Molecular Medicine Cattle Antibody Foot-and-mouth disease virus Adjuvant |
| Zdroj: | Vaccine. 36:7345-7352 |
| ISSN: | 0264-410X |
| Popis: | We investigated the serotype- and topotype versatility of a replication-deficient human adenovirus serotype 5 vectored foot-and-mouth disease (FMD) vaccine platform (AdtFMD). Sixteen AdtFMD recombinant subunit monovalent vaccines targeting twelve distinct FMD virus (FMDV) serotype/topotypes in FMD Regional Pools I-VII were constructed. The AdtA24 serotype conditionally licensed vaccine served as the basis for vaccine design and target dose for cattle clinical trials. Several vaccines contained an additional RGD motif genetic insertion in the adenovector fiber knob, and/or a full-length 2B gene insertion in the FMDV P1 gene cassette. In 13 of the 22 efficacy studies conducted, naive control and AdtFMD vaccinated cattle were challenged intradermolingually at 2 weeks post-vaccination using a FMDV strain homologous to the AdtFMD vaccine strain. Each of the 16 AdtFMD vaccines were immunogenic based on the presence of homologous neutralizing antibodies in the serum of approximately 90% of total vaccinates (n = 375) on the day of challenge. Importantly, for 75% of vaccines tested, the effective dose that conferred 100% protection against clinical FMD was identical to or in some cases lower than, the minimum protective dose for the conditionally licensed AdtA24 vaccine formulated with ENABL® adjuvant. Results also confirmed the capability of the AdtFMD vaccine platform to differentiate infected from vaccinated animals (DIVA) across the five FMDV serotypes evaluated. Collectively, this comprehensive set of FMD cattle vaccine dose ranging studies highlights the serotype- and topotype versatility of the AdtFMD vaccine platform for further development, licensure, and application in FMD outbreak control and disease eradication efforts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect